| abstract |
The present invention provides a pharmaceutical composition which includes: a compound represented by formula (1), or N-[3-((4aS, 5R, 7aS)-2-amino-5-methyl-4a, 5, 7, 7a-tetrahydro-4H-furo[3, 4-d][1, 3]thiazine-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or pharmaceutically acceptable salts of these; and a salt of a compound provided with a C12-22 saturated aliphatic hydrocarbon group. |